Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025CNS Neuroscience & TherapeuticsOpen Access

The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐GlcNAcylation

View Full Paper
Ask AI
Bookmark
Share

Authors

RYRongxu YeWZWanghao ZhangHZHuayang Zhang

Discussion

Loading...

Member takes

Overview

This study demonstrates FR054 promotes ferroptosis and inhibits O-GlcNAcylation, enhancing TMZ efficacy in glioblastoma.

Key Points

  • Combining FR054 with temozolomide significantly enhances sensitivity in glioblastoma cells.
  • In vitro studies showed the combination therapy suppressed tumor progression and prolonged survival.
  • The research identifies PGM3 as a key enzyme linked to treatment resistance in glioblastoma patients.
  • Targeting the HBP pathway with FR054 reveals a novel therapeutic strategy against temozolomide resistance.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/68c23dc5b210217d6478f7c8https://doi.org/10.1111/cns.70546
View Full Paper
Ask AI
Bookmark
Share